Non-Small Cell Lung Cancer

New Reference: Encorafenib and Binimetinib in bRAF V600E Mutated NSCLC

2023-06-24

  • Study

    Phase II, single-arm study (PHAROS)
    Treatment-naïve and previously treated with BRAFV600E-mutant metastatic NSCLC
    Encorafenib +Bininmetinib q28 (n=98)


  • Efficacy

    ORR: 75.0% [62%-85%] in treatment naïve and 46% [30%-63%) in previously treated group
    mDOR: NR and 16.7 mos
    mPFS: NR and 9.3 mos [6.2-NR]

  • Safety

    Grade3 Aes: ALT increased (5%), AST increased (7%), diarrhea (4%), anemia (3%).


    • Journal of Clin Oncol 2023 JUN 04

    Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer.

    http://doi.org/10.1200/JCO.23.00774

    Reviewed by Elvin Chalabiyev, MD on Jun 24, 2023